Lets re-cap Novos price action story Over the last 12-24 months Novo Nordisk has gone from GLP1 market darling to one of the more financially bruising rides in largecap pharma
"Patients I see want their knees to feel better, their hips to feel better, their blood pressure to get better, their diabetes to get better," Levy said
USA 108 , 1666316668 (2011)
Glucagon receptor activation increases hepatic glucose output, promotes fat oxidation in the liver, increases energy expenditure, and enhances thermogenesis
This leads to a reduction in calorie intake, helping people lose weight gradually over time
This suggests the pain relief observed in the trial is not purely a downstream consequence of losing weight but may involve a separate pathway